News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Extended Benefit with Bronchitol in Second Phase III Cystic Fibrosis Trial
Pharmaxis today announced positive first results for the open label component of its second international Phase III trial of Bronchitol in people with cystic fibrosis.
Read full media release - pdf
Pharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol
Pharmaxis today announced that the Company held a pre-NDA meeting with the US Food and Drug Administration (FDA) on Friday 10 December 2010 .
Read full media release - pdf
Bronchitol Recommended for Approval by Australian Advisory Committee
Pharmaxis today announced that at its recent meeting, the Australian Advisory Committee on Prescription Medicines (ACPM) has recommended approval of Bronchitol (inhaled dry powder mannitol) for marketing in Australia for the treatment of cystic fibrosis.
Read full media release - pdf